Karl Schwartz, Artist advocateHeading for #ODAC advisory deliberation?
In the Phase III study, 125 patients received either placebo or Elevidys, the gene [study-drug] for Duchenne disease.
For the public: in #ClinicalResearch you must call your shot before taking it ... declare your primary endpoint that would be the basis for #FDA approval if met.
